Canfosfamide

A chemotherapy drug candidate

{{Drugbox | verifiedfields = changed | verifiedrevid = 477241282 | IUPAC_name = 1,3,2-Dioxaphospholane, 2-oxide, 2-[[4-[[bis(2-chloroethyl)amino]phenyl]amino]-2-oxoethyl]- | image = Canfosfamide.svg | image_size = 200px | image_alt = Chemical structure of Canfosfamide | image_caption = Chemical structure of Canfosfamide }}

Canfosfamide (also known as TLK286) is an investigational chemotherapy drug that was being developed for the treatment of various types of cancer. It belongs to the class of alkylating agents, which are compounds that work by adding an alkyl group to the DNA of cancer cells, thereby preventing their replication and leading to cell death.

Mechanism of Action

Canfosfamide is a prodrug, meaning it is administered in an inactive form and is metabolized into its active form within the body. The active metabolite of canfosfamide is a glutathione analog that targets cancer cells with high levels of glutathione S-transferase (GST), an enzyme often overexpressed in cancer cells. By exploiting the elevated GST levels, canfosfamide selectively targets and kills cancer cells while sparing normal cells.

Development and Clinical Trials

Canfosfamide was developed by Telik, Inc., a biopharmaceutical company. It underwent several phases of clinical trials to evaluate its efficacy and safety in treating different types of cancer, including ovarian cancer, non-small cell lung cancer, and breast cancer.

Phase I Trials

The initial phase I trials focused on determining the maximum tolerated dose and identifying any dose-limiting toxicities. These studies also aimed to understand the pharmacokinetics and pharmacodynamics of the drug.

Phase II Trials

In phase II trials, canfosfamide was tested for its efficacy in specific cancer types. The trials showed some promise, particularly in patients with ovarian cancer who had become resistant to standard chemotherapy treatments.

Phase III Trials

Phase III trials were conducted to compare canfosfamide with standard chemotherapy regimens. However, the results did not demonstrate a significant improvement in overall survival or progression-free survival compared to existing treatments.

Side Effects

As with many chemotherapy agents, canfosfamide is associated with a range of side effects. Common side effects include nausea, vomiting, fatigue, and myelosuppression, which is a decrease in the production of blood cells. These side effects are generally manageable with supportive care.

Current Status

Despite initial promise, the development of canfosfamide was eventually discontinued due to insufficient efficacy in clinical trials. However, the research contributed valuable insights into the design of targeted chemotherapy agents and the role of GST in cancer therapy.

Related Pages

• Chemotherapy
• Alkylating agent
• Glutathione S-transferase
• Ovarian cancer